Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Jianming Xu,Rongrui Liu,Yi Ba,Da Jiang,Mingxia Wang,Yulong Zheng,Jia Wei,Yuxian Bai,Lizhu Lin,Jianping Xiong,Xixi Zhu,Chuanhua Zhao,Ru Jia,Yun Zhang,Jianzhi Liu,Gairong Zhang,Guangze Li,Quanren Wang

Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

2019

Jianming Xu
Rongrui Liu
Yi Ba
Da Jiang
Mingxia Wang
Yulong Zheng
Jia Wei
Yuxian Bai
Lizhu Lin
Jianping Xiong
Xixi Zhu
Chuanhua Zhao
Ru Jia
Yun Zhang
Jianzhi Liu
Gairong Zhang
Guangze Li
Quanren Wang

4060Background: Fluzoparib (SHR3162) is an oral, selective PARP1 inhibitor. In our gastric cancer PDX model, fluzoparib + apatinib + paclitaxel demonstrated significant tumor growth inhibition as c...

Keywords:

Gastroesophageal Junction
Paclitaxel
Gastroenterology
PARP1
Pathology
Medicine
Internal medicine
Apatinib
Adenocarcinoma
in patient
Cancer research
Cancer
phase i study
Fluzoparib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations